Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04759586
Title Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Recruitment Recruiting
Gender
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

primary mediastinal B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: child | adult | senior
Covered Countries USA | CAN


No variant requirements are available.